Fluvastatin treatment and withdrawal: Effects on endothelial function

Angiology

Volumn 59, Issue 5, 2008, Pages 613-618

  Westphal, Sabine ^a,c   Abletshauser, Claudia ^b   Luley, Claus ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Novartis GmbH   (Germany)

^c Institute of Clinical Chemistry   (Germany)

Author keywords

Cessation of therapy; Flow mediated vasodilation; Fluvastatin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; PLACEBO;

ADULT; ARTICLE; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; DRUG WITHDRAWAL; EXTENDED DRUG RELEASE; FEMALE; HUMAN; IMMEDIATE DRUG RELEASE; LIPID BLOOD LEVEL; MALE; VASODILATATION;

BRACHIAL ARTERY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; TRIGLYCERIDES; VASODILATION;

EID: 53949098550     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708316005     Document Type: Article

References (20)

1. Suwaidi JA, Hamasaki S., Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000 ; 101: 948-954.
2. Schachinger V., Britten MB, Zeiher AM Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000 ; 101: 1899-1906.
3. Yeboah J., Crouse JR, Hsu FC, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007 ; 115: 2390-2397.
4. Fleming RM The pathogenesis of vascular disease. In: John C. Chang, ed. Textbook of Angiology. New York, NY: Springer-Verlag; 1999: 787-798.
5. Fleming RM The Fleming unified theory of vascular disease: a link between atherosclerosis, inflammation, and bacterially aggravated atherosclerosis (BAA). Angiology. 2000 ; 51: 87-89.
6. Tziomalos K., Athyros VG, Karagiannis A., Mikhailidis DP Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets. 2007 ; 11: 1143-1160.
7. Sakabe K., Fukuda N., Wakayama K., et al. Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients. Int J Cardiol. 2004 ; 94: 111-117.
8. Dogra GK, Watts GF, Chan DC, et al. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabet Med. 2005 ; 22: 239-242.
9. Lefer AM, Scalia R., Lefer DJ Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001 ; 49: 281-287.
10. Simons LA, Sullivan D., Simons J., et al. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis. 1998 ; 137: 197-203.
11. Wolfrum S., Jensen KS, Liao JK Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003 ; 23: 729-736.
12. McFarlane SI, Muniyappa R., Francisco R., et al. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002 ; 87: 1451-1458.
13. Taneva E., Borucki K., Wiens L., et al. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol. 2006 ; 97: 1002-1006.
14. Corretti MC, Anderson TJ, Benjamin EJ, et al. International brachial artery reactivity task force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: report of the International Brachial Artery Reactivity Task Force. Am Coll Cardiol. 2002 ; 39: 257-265.
15. Corsini A., Jacobson TA, Ballantyne CM Fluvastatin: clinical and safety profile. Drugs. 2004 ; 64: 1305-1323.
16. Corsini A. Fluvastatin: effects beyond cholesterol lowering. J Cardiovasc Pharmacol Ther. 2000 ; 5: 161-175.
17. Laufs U., Endres M., Custodis F., et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000 ; 102: 3104-3110.
18. Endres M., Laufs U. Discontinuation of statin treatment in stroke patients. Stroke. 2006 ; 37: 2640-2643.
19. Gertz K., Laufs U., Lindauer U., et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003 ; 34: 551-557.
20. Heeschen C., Hamm CW, Laufs U., et al. Withdrawal of statins in patients with acute coronary syndromes. Circulation. 2003 ; 107: e27.